Investor deep dive
ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor
Successful AstraZeneca lupus study bodes well for ImmuPharma's Lupuzor - analyst
Dr Navid Malik, Head of Life Sciences Research, tells Proactive London's Andrew Scott the recent positive update for AstraZeneca's lupus drug Anifrolumab is not only positive for the Lupus field but also serves as a reminder that ImmuPharma PLC’s (LON:IMM) Lupuzor drug could represent a highly successful product.
AstraZeneca announced positive topline data from its second Phase III clinical trial in Lupus patients, comparing Anifrolumab to the current standard of care.
Quick facts: ImmuPharma PLC
Market Cap: £16.26 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE